Show simple item record

dc.contributor.authorAydin, Mehtap
dc.contributor.authorAsan, Ali
dc.contributor.authorSayan, Murat
dc.contributor.authorAkhan, Sila
dc.contributor.authorKoruk, Suda Tekin
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorSirmatel, Fatma
dc.contributor.authorEraksoy, Haluk
dc.contributor.authorTuna, Nazan
dc.contributor.authorKose, Sukran
dc.contributor.authorKaya, Ali
dc.contributor.authorTulek, Necla Eren
dc.contributor.authorDemir, Nazlim Aktug
dc.contributor.authorMistik, Resit
dc.contributor.authorOrmen, Bahar
dc.contributor.authorKorkmaz, Fatime
dc.contributor.authorYildirmak, Taner
dc.contributor.authorUral, Onur
dc.contributor.authorTurgut, Huseyin
dc.contributor.authorGunal, Ozgur
dc.contributor.authorDemirtuk, Nese
dc.date.accessioned2019-05-14T13:21:06Z
dc.date.available2019-05-14T13:21:06Z
dc.date.issued2018
dc.identifier.issn1735-143X
dc.identifier.urihttps://neoscriber.org/cdn/serve/3144a/d34318d6d0317c0672b0d1143e5ff4ce050f5426/hepatmon-18-01-12472.pdf
dc.identifier.urihttp://hdl.handle.net/11727/3286
dc.description.abstractBackground: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy leading to the production of a large number of virions with single and double mutations. The mutations, in turn, are associated with the development of drug resistance to nucleos(t)ide analogs (NUCs) in patients before and during NUCs therapy. Objectives: The current study aimed at investigating the molecular characterization of HBV in Turkish patients with chronic hepatitis B (CHB) infection. Methods: Polymerase chain reaction (PCR) amplification and direct sequencing procedures were used to analyze mutations. The detected drug resistance mutations were divided into the nucleos(t) ide analogs primary, partial, and compensatory resistance groups. The amino acid substitutions of hepatitis B surface antigen (HBsAg) were categorized into antiviral drug - associated potential vaccine-escape mutations (ADAPVEMs) and typical HBsAg amino acid substitutions, which included hepatitis B hyperimmunoglobulin (HBIg) - selected escape mutation, vaccine escape mutation, hepatitis B misdiagnosis, and immune - selected amino acid substitutions. Results: The number of patients included in the study was 528 out of which 271 (51.3%) were treatment - naive and 351 (66.3%) were hepatitis B e antigen (HBeAg) - negative. Moreover, 325 (61.6%) were males with a mean age of 38 years (range: 18 - 69). Primary, partial, and compensatory resistance to NUCs was reported in 174 (32.9%) patients. Six different ADAPVEM motifs were determined in both treatment - naive and treatment - experienced patients, namely, sF161L/rtI169X, sE164D/rtV173L, sL172L/rtA181T, sL173F/rtA181V, sS195M/rtM204V, and sS196L/rtM204I. The prevalence of ADAPVEMs and typical HBsAg escape mutations was 5.3% (n = 28) and 34.8% (n = 184), respectively. Conclusions: The analysis of drug resistance should constitute a fundamental part of the follow - up period of patients with CHB undergone treatment with NUCs. The surveillance of development of drug resistance mutations, while receiving treatment for hepatitis B is of paramount importance to monitor and control the emerging resistance.en_US
dc.language.isoengen_US
dc.relation.isversionof10.5812/hepatmon.12472en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis B Virusen_US
dc.subjectSequence Analysisen_US
dc.subjectHBsAgen_US
dc.subjectAntiviral Drug Resistanceen_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectHBV Polymeraseen_US
dc.titleMolecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkeyen_US
dc.typearticleen_US
dc.relation.journalHEPATITIS MONTHLYen_US
dc.identifier.volume18en_US
dc.identifier.issue1en_US
dc.identifier.wos000429311800001


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record